OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Smith on PI3K Inhibitors in CLL

November 2nd 2019

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Kaubisch on Treatment Options for HCC

November 2nd 2019

Andreas Kaubisch, MD, discusses available treatment options for hepatocellular carcinoma.

Dr. Sonpavde on the Safety Profile of Erdafitinib in Bladder Cancer

November 2nd 2019

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Dr. Park on Updates With CAR T Cells in ALL

November 1st 2019

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Mato on Rituximab Biosimilars in CLL

November 1st 2019

Anthony R. Mato, MD, MSCE, discusses the introduction of rituximab biosimilars in chronic lymphocytic leukemia.

Dr. Benson on Frontline Treatment Considerations in mCRC

November 1st 2019

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Dr. Tabbara on Treatment for Transplant-Eligible and -Ineligible Patients With Multiple Myeloma

November 1st 2019

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer Surgery

November 1st 2019

Sarah Ferguson, MD, discusses how the results from the LACC trial, which compared minimally invasive surgery with open surgery in patients with IA1, IA2, or IB1 cervical cancer, are impacting surgery in the cervical cancer field.

Dr. Abou-Alfa on the Results of the ClarIDHy Trial in Advanced Cholangiocarcinoma

November 1st 2019

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

Dr. Domchek on Results of the MEDIOLA Trial in BRCA-Mutated Metastatic Breast Cancer

November 1st 2019

Susan Domchek, MD, discusses the results of the phase II MEDIOLA trial in germline BRCA-mutated metastatic breast cancer.

Dr. Mok on Overall Survival Data From the ALEX Trial in ALK+ Lung Cancer

November 1st 2019

Tony S. K. Mok, MD, BMSc, FRCPC, discusses overall survival from the phase III ALEX trial in ALK-positive lung cancer.

Dr. Cohen on the DREAMM-2 Trial in Multiple Myeloma

October 31st 2019

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

Dr. Mateos on Posthoc Analysis of ARROW Study in Multiple Myeloma

October 31st 2019

María-Victoria Mateos, MD, PhD, discusses the rationale for the posthoc analysis of the phase III ARROW study in multiple myeloma.

Dr. Usmani on CAR T Cells, Bispecific Antibodies, and ADCs in Multiple Myeloma

October 31st 2019

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

Dr. Kerrigan on Remaining Challenges in ROS1+ NSCLC

October 31st 2019

Katie Kerrigan, MD, discusses remaining challenges in the treatment of patients with ROS1-positive non–small cell lung cancer.

Dr. Saba on Immunotherapy/Radiation Combo in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

Dr. Kumar on Implications of BELLINI Trial in Relapsed/Refractory Multiple Myeloma

October 31st 2019

Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Mohler on Guidelines for Recording Family History in Prostate Cancer

October 31st 2019

James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.

Dr. Rugo on Rationale for the ELAINE Study in ESR1-Mutated ER+/HER2- Breast Cancer

October 31st 2019

Hope S. Rugo, MD, discusses the rationale for the phase II ELAINE study with lasofoxifene in patients with ESR1-mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer.